US Gene Therapy for Hemophilia Market Industry Trends and Forecast to 2034: Segmented by (Type, Vector, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$182.9 MnPlaceholder estimate
Estimate 2025$233.3 Mn46% of the global market
Projected 2034$2.09 Bn 796.7%Adds $1.86 Bn over 9 forecast years
CAGR 2025–203427.6%Faster than 97% of 180 Pharmaceuticals markets here
Key players5
US is 46.02% of the global market.
In North America, the largest is US (this report) at $233.3 Mn.
12 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Gene Therapy for Hemophilia Market Analysis Executive Summary
Gene therapies for hemophilia give patients a working copy of the clotting factor gene, so they may need fewer or no regular infusions.
Key segments of the gene Therapy for Hemophilia market include type (Hemophilia A and Hemophilia B) and vector (AAV5 and AAV Other Serotypes).
US Gene Therapy for Hemophilia market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Gene Therapy for Hemophilia Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Therapy for Hemophilia market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Therapy for Hemophilia market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for Gene Therapy for Hemophilia Market in US
The gene Therapy for Hemophilia market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Gene Therapy for Hemophilia Market in US
Gene Therapy for Hemophilia in the US: rules, payment and research
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 12 studies on Gene Therapy for Hemophilia that are recruiting, active or about to start in the US.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Therapy for Hemophilia. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Vector
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 BioMarin
7.2 CSL Behring
7.3 Pfizer
7.4 Roche
7.5 Sangamo Therapeutics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The gene Therapy for Hemophilia market can be segmented based on various criteria, including type, vector and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Gene Therapy for Hemophilia right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Gene Therapy for Hemophilia in context
The US compared
Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
How big is the Gene Therapy for Hemophilia market in the US?
Placeholder estimate: about $233.3 Mn in 2025, rising to about $2.09 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Gene Therapy for Hemophilia market in the US growing?
Placeholder estimate: about 27.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Gene Therapy for Hemophilia market report cover?
The report splits the market by type (Hemophilia A, Hemophilia B), vector (AAV5, AAV Other Serotypes) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Gene Therapy for Hemophilia market?
Key players include BioMarin, CSL Behring, Pfizer Inc., Roche and Sangamo Therapeutics.
What is driving the Gene Therapy for Hemophilia market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
Who regulates Gene Therapy for Hemophilia in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Gene Therapy for Hemophilia are running in the US?
12 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Gene Therapy for Hemophilia?
PubMed lists 291 papers on Gene Therapy for Hemophilia added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.